Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference

Jie Chen1, Xiaoyan Liu, Jie Zhang

  • 1Department of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, China.

Insights

High-mobility group box 1 (HMGB1) is elevated in ovarian cancer, driving proliferation, invasion, and metastasis. Targeting HMGB1 may offer a new therapeutic strategy for epithelial ovarian cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • High-mobility group box 1 (HMGB1) is a protein involved in cancer development.
  • The role of HMGB1 in ovarian cancer remains largely uncharacterized.

Purpose of the Study:

  • To investigate the function of HMGB1 in ovarian cancer progression.
  • To explore HMGB1 as a potential therapeutic target for ovarian cancer.

Main Methods:

  • cDNA microarray analysis to identify HMGB1 expression.
  • Lentivirus-mediated shRNA to knockdown HMGB1 in ovarian cancer cell lines.
  • Real-time RT-PCR, Western blot, and IHC to confirm knockdown efficacy.
  • Assays for cell proliferation, cell cycle, apoptosis, invasion, and metastasis.

Main Results:

  • HMGB1 expression was significantly elevated in highly invasive ovarian cancer cells.
  • HMGB1 knockdown suppressed proliferation, induced G1/G0 cell cycle arrest, and promoted apoptosis.
  • HMGB1 knockdown inhibited invasion and metastasis by downregulating MMP2 and MMP9.
  • Elevated serum HMGB1 levels were observed in epithelial ovarian cancer patients.

Conclusions:

  • HMGB1 is a key driver of ovarian cancer growth, invasion, and metastasis.
  • HMGB1 plays a significant role in ovarian cancer pathogenesis.
  • HMGB1 represents a promising therapeutic target for ovarian cancer treatment.

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...